Associated tags: ICE, Patient, Cancer, ROCK, Biotechnology, Pharmaceutical industry, Affimer, NK, Vaccine
Locations: KOREA, SPAIN, JAPAN, CA, MANNHEIM,, DE, GERMANY, NETHERLANDS, SEOUL, CHICAGO, NY, NEW YORK
AACR,
KTH Royal Institute of Technology,
ADCC,
Cancer,
NK,
Cell,
Patient,
Annual general meeting,
Karolinska Institute,
Poster,
IND,
CD30,
FC,
Vaccine,
Affimer The preclinical data demonstrate the ability of AFM13, Affimed’s CD16A/CD30-targeting innate cell engager (ICE®), to induce serial killing of tumor cells, while preserving CD16A shedding.
Key Points:
- The preclinical data demonstrate the ability of AFM13, Affimed’s CD16A/CD30-targeting innate cell engager (ICE®), to induce serial killing of tumor cells, while preserving CD16A shedding.
- The poster, shown at the Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, shared results from a live-cell microchip screening with single cell resolution.
- AFM13 increased NK killing efficiency of CD30-positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
- “AFM13 increased NK cell-mediated serial killing of tumor cells, even when they express low levels of CD30,” said Prof. Björn Önfelt.
Neutropenia,
AACR,
REDIRECT,
Affimer,
OS,
Cancer,
American Association for Cancer Research,
PFS,
ORR,
Dor,
Patient,
CR,
Samsung Medical Center,
Fever,
Nanakaly Hospital for Hematology & Oncology,
Lymphoma,
IRR,
Safety,
Disease,
Pharmaceutical industry,
PTCL Primary efficacy measures include an ORR of 32.4% and a CR rate of 10.2%.
Key Points:
- Primary efficacy measures include an ORR of 32.4% and a CR rate of 10.2%.
- Key secondary and exploratory outcome measures include safety, durability of response, progression free survival and overall survival.
- The safety profile of AFM13 was well managed and consistent with previously reported data of prior and ongoing clinical studies with AFM13.
- These data substantiate the next step towards further development of AFM13 in PTCL,” said Dr. Adi Hoess, Chief Executive Officer at Affimed.
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 2, 2023, to regain compliance.
Key Points:
- In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 2, 2023, to regain compliance.
- If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement).
- Such transfer would provide the Company with an additional 180 calendar days, or until April 1, 2024, to regain compliance.
- The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.
Retrieved on:
Wednesday, March 29, 2023
Myelodysplastic syndrome,
Index,
Affimer,
Clinical trial,
Cancer,
Pharmacokinetics,
NK,
Acute myeloid leukemia,
MDS,
AML,
Patient,
MTD,
News,
Acute leukemia,
Safety,
Pharmaceutical industry,
MD "I’m proud of this milestone as AFM28 represents Affimed’s third wholly owned ICE® molecule to enter the clinic.
Key Points:
- "I’m proud of this milestone as AFM28 represents Affimed’s third wholly owned ICE® molecule to enter the clinic.
- We are happy to see our first patient successfully dosed and look forward to the continued study of this novel agent.
- The study (AFM28-101) is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AFM28 monotherapy in patients with CD123-positive r/r AML.
- Affimed also intends to develop AFM28 in combination with allogeneic natural killer (NK) cell therapy.
Affimed's consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB).
Key Points:
- Affimed's consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB).
- Research and development expenses for 2022 increased by 21.3% from €81.5 million in 2021 to €98.8 million in 2022.
- Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
- Affimed will host a conference call and webcast on March 23, 2023, at 8:30 a.m. EDT / 13:30 CET to discuss full year and Q4 2022 financial results and corporate developments.
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023.
Key Points:
- HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023.
- The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.
- The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
PTCL,
KTH Royal Institute of Technology,
Cancer,
AACR,
Antibody-dependent cellular cytotoxicity,
Annual general meeting,
Abstract,
Cell,
Antibody,
ADCC,
Patient,
Karolinska Institute,
Natural killer T cell,
CD30,
NK,
Vaccine,
Pharmaceutical industry An oral presentation will show detailed results from the AFM13 REDIRECT study evaluating the treatment of patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL).
Key Points:
- An oral presentation will show detailed results from the AFM13 REDIRECT study evaluating the treatment of patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL).
- In addition, a poster presentation will highlight results from the collaboration study with Prof. Björn Önfelt, further elucidating AFM13’s mechanism of action.
- Antibody-Dependent Cellular Cytotoxicity (ADCC) is a powerful mechanism of Natural Killer (NK) cells to kill antibody-opsonized target cells.
- However, ADCC mediated by conventional antibodies has its limitations in killing of tumor cells commonly being characterized by low tumor antigen expression.
Under the grant, awarded to AbCheck by the Ministry of Industry and Trade of the Czech Republic in 2019, the Company has received a total of more than €1 million.
Key Points:
- Under the grant, awarded to AbCheck by the Ministry of Industry and Trade of the Czech Republic in 2019, the Company has received a total of more than €1 million.
- As of December 31, 2022, all work stipulated in the grant agreement had been completed.
- Importantly, AbCheck did not only meet all objectives of the original project plan, but successfully developed its novel microfluidics technology beyond the foreseen scope of the project.
- “Our novel microfluidics technology has already been applied in multiple research projects identifying functional antibodies to various targets.
Retrieved on:
Wednesday, February 22, 2023
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.
Key Points:
- HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.
- A live webcast of the fireside chat will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- A replay of the call will be archived on Affimed’s website for 30 days after the call.
- For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.
Retrieved on:
Tuesday, February 21, 2023
PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.
Key Points:
- PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.
- Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile.
- AbCheck’s high-class drug discovery platform centered on the Company’s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein therapeutics.
- “Our proprietary microfluidics platform, which enables functional screening for millions of single cells per day, has been specifically designed to deliver antibodies against targets with particularly complex Target Product Profiles.
